Last reviewed · How we verify
Pseudomonas aeruginosa
Pseudomonas aeruginosa is a broad-spectrum antibiotic that targets bacterial cell wall synthesis.
Pseudomonas aeruginosa is a broad-spectrum antibiotic that targets bacterial cell wall synthesis. Used for Pneumonia, Urinary tract infections, Skin and soft tissue infections.
At a glance
| Generic name | Pseudomonas aeruginosa |
|---|---|
| Sponsor | Qilu Hospital of Shandong University |
| Drug class | beta-lactam antibiotic |
| Target | penicillin-binding proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | FDA-approved |
Mechanism of action
Pseudomonas aeruginosa is a bacterium that can cause a variety of infections, and this antibiotic works by inhibiting the enzyme responsible for peptidoglycan synthesis in the bacterial cell wall, ultimately leading to cell lysis and death.
Approved indications
- Pneumonia
- Urinary tract infections
- Skin and soft tissue infections
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Allergic reactions
- Seizures
Key clinical trials
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis (PHASE3)
- mexB Efflux Pump Gene Expression, Activity and Biofilm Formation in Clinical Isolates of Pseudomonas Aeruginosa
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization (PHASE2)
- Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa) (PHASE1, PHASE2)
- Pseudomonas Aeruginosa Injection Combined With Polyvinylpyrrolidone-Iodine in Immediate Breast Reconstruction Surgery With Implants (NA)
- Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pseudomonas aeruginosa CI brief — competitive landscape report
- Pseudomonas aeruginosa updates RSS · CI watch RSS
- Qilu Hospital of Shandong University portfolio CI